GlassScriptPhysician profile
Dodi L Bowen
NPI 1811147036
$1,577.39
in general payments reported to CMS, 2019-2025
15 companies · $560 in 2025
The $560 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $271 · 2023: $522 · 2024: $224 · 2025: $560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,206 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,206.05 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $651.53 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $406.94 | 2022-2025 | Keytruda |
| Sobi, INC | $128.44 | 2023-2025 | |
| Daiichi Sankyo INC. | $83.94 | 2022-2024 | Enhertu, Injectafer |
| Celgene Corporation | $77.76 | 2022-2025 | Pomalyst, Opdivo |
| Astellas Pharma US INC | $46.26 | 2025 | Padcev |
| Foundation Medicine, INC. | $29.84 | 2023 | |
| Novocure INC. | $24.00 | 2025 | Optune Lua (Novottf-200t) |
| E.R. Squibb & Sons, L.L.C. | $23.54 | 2025 | |
| Alexion Pharmaceuticals, INC. | $19.92 | 2023 | Ultomiris |
| Si-Bone, INC. | $18.27 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.85 | 2025 | |
| Pfizer INC. | $17.53 | 2025 | |
| Jazz Pharmaceuticals INC. | $16.89 | 2023 | |
| Kyowa Kirin, INC. | $14.68 | 2024 | Poteligeo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dodi Bowen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.